THRB and metabolic dysfunction-associated steatohepatitis: A major therapeutic breakthrough occurred in March 2024, when the U.S. Food and Drug Administration (FDA) approved Resmetirom (brand name Rezdiffra), a selective thyroid hormone receptor-β (THR-β) agonist, for the treatment of adults with noncirrhotic NASH and moderate to advanced fibrosis [10].